Phase 3 Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Crohn's Disease (a condition causing inflammation in the digestive tract), including a form involving abnormal tunnels between body parts called fistulizing Crohn's Disease, lasting at least 12 weeks, confirmed at some point in the past by imaging, tissue samples, or a camera examination of the gut
- People whose Crohn's Disease is moderately to severely active, based on a standard disease activity scoring system called the CDAI, with a score between 220 and 450 at the start of the trial
- People whose gut shows signs of active inflammation and ulcers (open sores) on a camera examination of the bowel done during the screening process, meeting specific scoring thresholds depending on which part of the gut is affected
- People whose treating doctor considers their disease suitable for the treatment schedules used in this trial
- People who are able to follow the medication rules set out in the trial protocol
Who may not be able to join:
- People who have complications of Crohn's Disease such as narrowing of the bowel causing symptoms, short gut syndrome, an active draining opening in the abdomen, significant fistula disease, or other complications that are expected to need surgery within the next year, or that could interfere with measuring treatment response
- People who currently have, or are suspected to have, a pocket of infection (abscess) in the body
- People who have an active fistula (an abnormal tunnel between body parts) at the start of the trial and are expected to need surgery for it
- People who have had any bowel removal surgery within the past 24 weeks, or any other major abdominal or significant surgery within the past 12 weeks before the first dose
- People who currently have cancer, or who have had cancer at any point in the 5 years before the screening process
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Deep Remission at Week 52
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.